ArticleChinese journal of integrative medicine2026
Prevention and Treatment of Doxorubicin and Trastuzumab-Induced Cardiotoxicity with Compound Danshen Dripping Pill.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo elucidate the therapeutic effect and mechanism of Compound Danshen Dripping Pill (CDDP) on cardiotoxicity caused by doxorubicin (DOX) and trastuzumab (TRZ)
methodsEighteen Sprague-Dawley (SD) rats were randomly divided into the normal group (normal saline), the model group (DOX/TRZ), and CDDP administration group (DOX/TRZ+CDDP), by a random number table, with 6 rats in each group. Rats' were administered either DOX or saline via tail vein injection 6 times over an 11-day period. One week later, they received either TRZ or saline via intraperitoneal injection 6 times over another 11-day period. All rats received CDDP or saline via oral gavage continuously for 36 days. Then, echocardiography was performed on the rats, and biochemical parameters of blood and heart samples were determined. Rats' feces were taken for intestinal flora testing and plasma metabolites were analyzed using untargeted metabolomics.
resultsEchocardiographic assessment in rats demonstrated that DOX/TRZ induced cardiac dysfunction, whereas CDDP significantly ameliorated this impairment (P<0.05 or P<0.01). Furthermore, results revealed that DOX/TRZ elevated cardiac injury indicators (left ventricular ejection fraction, fractional shortening, cardiac troponin I, creatine kinase, creatine kinase-MB), while CDDP treatment significantly reduced these levels (P<0.05 or P<0.01). Plasma metabolite analysis revealed enrichment in tryptophan metabolism, tricarboxylic acid cycle, and phenylalanine metabolism. Intestinal microbiota analysis showed increased richness and altered abundance of certain bacteria (Clostridia_UCG-014 and Lactobacillus) with CDDP treatment.
conclusionsCDDP can prevent and protect against DOX/TRZ-induced cardiac injury. It influences tryptophan metabolism by modulating Clostridia_UCG-014 abundance, inhibits indole-3-carboxylic acid levels, increases kynurenine levels, thereby exerting anti-cardiotoxic effects.
Indexed as
Identifiers
41252114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.